Healthcare
MiNK Therapeutics, Inc.(INKT)
Live Price
Offline$12.14
-0.57% today
1Y Change
+62.45%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -1.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MiNK Therapeutics, Inc. (INKT) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $12.14 and up 62.5% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -1.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -1.0%, free cash flow -61908.1% with operating margin 0.0% and ROIC -195.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INKT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -1.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -4.9% | -3.0% | +11.6% |
2026 Mar 17, 2026 | +23.5% | -1.1% | -10.6% | +35.2% |
2025 Nov 14, 2025 | +24.4% | -5.9% | -17.2% | -4.5% |
Benchmark Edge
INKT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INKT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INKT Max Drawdown
-86.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INKT and SPY.
Company Overview
MiNK Therapeutics, Inc.
NASDAQ Capital Market
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
- Leadership
- Jennifer S. Buell
- IPO Date
- Oct 15, 2021
- Employees
- 23
- Street Address
- 149 Fifth Avenue
- Mailing
- New York City, NY, 10010
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 994 8250
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 1080.4
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -1.0%
- Free Cash Flow
- -61908.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 66.9%
- ROIC
- -195.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.